Repatha (evolocumab) is an antibody pharmaceutical. Evolocumab was first approved as Repatha on 2015-07-17. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
|Indication||atherosclerosis, dyslipidemias, hypercholesterolemia|
|Drug Class||Monoclonal antibodies: fully human, cardiovascular indications|